Currently, there are 136.27M common shares owned by the public and among those 123.47M shares have been available to trade.
Insiders at the company have transacted a total of 12 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 12 of these insider trades were purchases, accounting for 436,139 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 3.2500, up 3.41%. The company’s stock has a 5-day price change of 5.65% and 72.36% over the past three months. XERS shares are trading 35.32% year to date (YTD), with the 12-month market performance up to 123.94% higher. It has a 12-month low price of $1.13 and touched a high of $3.26 over the same period. XERS has an average intraday trading volume of 2.07 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 9.08%, 21.77%, and 37.23% respectively.
Institutional ownership of Xeris Biopharma Holdings Inc (NASDAQ: XERS) shares accounts for 41.91% of the company’s 136.27M shares outstanding.
It has a market capitalization of $439.22M and a beta (3y monthly) value of 1.66. The earnings-per-share (ttm) stands at -$0.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.68% over the week and 5.70% over the month.
Analysts forecast that Xeris Biopharma Holdings Inc (XERS) will achieve an EPS of -$0.1 for the current quarter, -$0.09 for the next quarter and -$0.27 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.13 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was -$0.1 a year ago. Earnings per share for the fiscal year are expected to increase by 44.46%, and 41.96% over the next financial year.
Looking at the support for the XERS, a number of firms have released research notes about the stock. Craig Hallum stated their Buy rating for the stock in a research note on August 28, 2023, with the firm’s price target at $4.50. Jefferies coverage for the Xeris Biopharma Holdings Inc (XERS) stock in a research note released on October 21, 2022 offered a Buy rating with a price target of $4. Craig Hallum was of a view on April 28, 2022 that the stock is Buy, while SVB Leerink gave the stock Outperform rating on November 17, 2021, issuing a price target of $6. H.C. Wainwright on their part issued Buy rating on October 29, 2021.
